Studying How Different Doses of Tranexamic Acid and Clotting Times Affect Bleeding in Adults Undergoing Heart Surgery

What this Trial Is About

Researchers are evaluating how different doses of tranexamic acid and levels of activated clotting time ACT affect bleeding and the need for blood transfusions in adults undergoing cardiac surgery with cardiopulmonary bypass. This study aims to determine whether higher doses of tranexamic acid or lower ACT levels during surgery can reduce bleeding and transfusion amounts. The trial is a randomized, phase 4 interventional study sponsored by Taichung Veterans General Hospital. Participants will be divided into four groups based on two factors the dose of tranexamic acid high dose of 50 mgkg or low dose of 20 mgkg and the ACT level maintained during surgery either 400-600 seconds or above 600 seconds. Tranexamic acid will be administered via a pump starting at the beginning of anesthesia until the full dose is given. Each group combines one dose level with one ACT range to compare outcomes. During the study, medical records of patients who had cardiac surgery between December 1, 2023, and December 31, 2026, will be analyzed. Researchers will measure the volume of bleeding within 24 hours after surgery and the amount of blood transfused during the procedure, averaging about 6 hours. They will also monitor mortality within 30 days. The findings aim to improve monitoring and medication management during cardiac surgeries. Participation involves data collection from medical records without additional procedures.

The Effect of ACT and Tranexamic Acid on Bleeding in Cardiac Surgery